Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: DST006
MIFTS: 46

Diastolic Heart Failure

Categories: Cardiovascular diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Diastolic Heart Failure

About this section

MalaCards integrated aliases for Diastolic Heart Failure:

Name: Diastolic Heart Failure 12 15 17
Heart Failure, Diastolic 45 74

Classifications:

MalaCards categories:
Anatomical: Cardiovascular diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:9775
ICD9CM 36 428.3 428.30
MeSH 45 D054144
ICD10 34 I50.30
UMLS 74 C1135196
Sources

Summaries for Diastolic Heart Failure

About this section
MalaCards based summary : Diastolic Heart Failure, also known as heart failure, diastolic, is related to congestive heart failure and mitral valve insufficiency. An important gene associated with Diastolic Heart Failure is ACE (Angiotensin I Converting Enzyme), and among its related pathways/superpathways are Development Angiotensin activation of ERK and Immune response IL-23 signaling pathway. The drugs Atorvastatin and Spironolactone have been mentioned in the context of this disorder. Affiliated tissues include heart, kidney and testes, and related phenotypes are Reduced mammosphere formation and behavior/neurological

Sources

Related Diseases for Diastolic Heart Failure

About this section

Diseases related to Diastolic Heart Failure via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 111)
# Related Disease Score Top Affiliating Genes
1 congestive heart failure 30.4 ACE AGTR1 NPPB
2 mitral valve insufficiency 30.4 ACE NPPB
3 systolic heart failure 30.4 ACE NPPB
4 end stage renal failure 30.0 ACE AGT AGTR1
5 renal hypertension 30.0 ACE AGTR1 NPPB
6 hypertrophic cardiomyopathy 29.9 ACE ANKRD1 MYBPC3
7 pulmonary hypertension 29.9 ACE NOS3 NPPB
8 atrial standstill 1 29.8 ACE MYBPC3 NPPB
9 pulmonary edema 29.8 ACE NOS3 NPPB
10 diabetes mellitus 29.6 ACE AGT AGTR1 NOS3
11 atrial fibrillation 29.6 ACE AGT AGTR1 MYBPC3 NPPB
12 autosomal dominant polycystic kidney disease 29.5 ACE AGT NOS3
13 sleep apnea 29.5 ACE NOS3 NPPB
14 coronary artery anomaly 29.5 ACE AGTR1 NOS3 NPPB
15 hypertensive heart disease 29.5 ACE AGT AGTR1 MMP2 NPPB
16 kidney disease 29.4 ACE AGT AGTR1 NOS3 NPPB
17 pre-eclampsia 29.4 AGT AGTR1 NOS3
18 chronic kidney failure 29.4 ACE AGT AGTR1 NOS3 NPPB
19 diabetes mellitus, noninsulin-dependent 29.2 ACE AGT AGTR1 NOS3
20 arteries, anomalies of 29.2 ACE AGT AGTR1 NOS3 NPPB
21 heart disease 28.8 ACE AGTR1 ANKRD1 MYBPC3 NOS3 NPPB
22 myocardial infarction 28.4 ACE AGT AGTR1 MMP2 NOS3 NPPB
23 rere-related disorders 11.2
24 pediatric hypertension 10.3 ACE AGT
25 hypertensive nephropathy 10.3 ACE AGTR1
26 anterolateral myocardial infarction 10.3 ACE NPPB
27 meningococcal infection 10.3 AGT AGTR1
28 left bundle branch hemiblock 10.2 ACE NPPB
29 syndrome of inappropriate antidiuretic hormone 10.2 ACE NPPB
30 nephrosclerosis 10.2 ACE AGTR1
31 idiopathic edema 10.2 ACE NPPB
32 aortic valve insufficiency 10.2 ACE NPPB
33 familial hypertension 10.2 AGT AGTR1
34 vesicoureteral reflux 1 10.2 AGT AGTR1
35 interstitial nephritis 10.2 ACE AGT
36 heart conduction disease 10.2 ACE NPPB
37 obstructive nephropathy 10.1 ACE AGT
38 heart valve disease 10.1 ACE NPPB
39 posterior urethral valves 10.1 ACE AGT AGTR1
40 microvascular complications of diabetes 3 10.1 ACE AGT AGTR1
41 anuria 10.1 ACE AGT AGTR1
42 malignant hypertension 10.1 ACE AGT AGTR1
43 fibromuscular dysplasia 10.1 ACE AGT AGTR1
44 renal tubular dysgenesis 10.1 ACE AGT AGTR1
45 renal dysplasia 10.1 ACE AGT AGTR1
46 constrictive pericarditis 10.1
47 pericarditis 10.1
48 amyloidosis 10.1
49 coronary stenosis 10.1 ACE NPPB
50 intrinsic cardiomyopathy 10.1 ACE MYBPC3

Graphical network of the top 20 diseases related to Diastolic Heart Failure:



Diseases related to Diastolic Heart Failure
Sources

Symptoms & Phenotypes for Diastolic Heart Failure

About this section

GenomeRNAi Phenotypes related to Diastolic Heart Failure according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.02 AGTR1 ANKRD1 MADD MMP2 MYBPC3

MGI Mouse Phenotypes related to Diastolic Heart Failure:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.8 ACE AGT AGTR1 ANKRD1 MADD MYBPC3
2 cardiovascular system MP:0005385 9.7 ACE AGT AGTR1 ANKRD1 MMP2 MYBPC3
3 adipose tissue MP:0005375 9.62 ACE AGT AGTR1 NOS3
4 homeostasis/metabolism MP:0005376 9.56 ACE AGT AGTR1 ANKRD1 MADD MMP2
5 muscle MP:0005369 9.02 AGT ANKRD1 MMP2 MYBPC3 NOS3
Sources

Drugs & Therapeutics for Diastolic Heart Failure

About this section

Drugs for Diastolic Heart Failure (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 127)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Atorvastatin Approved Phase 4,Not Applicable 134523-00-5 60823
2
Spironolactone Approved Phase 4,Phase 3,Not Applicable 1952-01-7, 52-01-7 5833
3
Eplerenone Approved Phase 4,Phase 2,Phase 3,Not Applicable 107724-20-9 443872 150310
4
Angiotensin II Approved, Investigational Phase 4,Phase 3 11128-99-7, 68521-88-0, 4474-91-3 172198
5
Valsartan Approved, Investigational Phase 4,Phase 3 137862-53-4 60846
6
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Phase 2 68-04-2
7
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
8
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
9
Nebivolol Approved, Investigational Phase 4 152520-56-4, 99200-09-6, 118457-14-0 71301
10
Adenosine Approved, Investigational Phase 4 58-61-7 60961
11
Regadenoson Approved, Investigational Phase 4 313348-27-5 219024
12
Empagliflozin Approved Phase 4 864070-44-0
13
Ambrisentan Approved, Investigational Phase 4 177036-94-1 6918493
14
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
15
Glucagon Approved Phase 4 16941-32-5
16
Norethindrone Approved Phase 4 68-22-4 6230
17
Polyestradiol phosphate Approved Phase 4 28014-46-2
18
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
19
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 77-92-9 311
20 Lipid Regulating Agents Phase 4,Not Applicable
21 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Not Applicable
22 Antimetabolites Phase 4,Not Applicable
23 Anticholesteremic Agents Phase 4,Not Applicable
24 Hypolipidemic Agents Phase 4,Not Applicable
25 Natriuretic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Diuretics, Potassium Sparing Phase 4,Phase 3,Phase 2,Not Applicable
27 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Phosphodiesterase Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
29 Phosphodiesterase 5 Inhibitors Phase 4,Phase 3,Phase 2
30 Vasodilator Agents Phase 4,Phase 3,Phase 2,Not Applicable
31 Mineralocorticoids Phase 4,Phase 3,Phase 2,Not Applicable
32 Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
33 diuretics Phase 4,Phase 3,Phase 2,Not Applicable
34 Mineralocorticoid Receptor Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
35 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
36 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Not Applicable
37 Angiotensin Receptor Antagonists Phase 4,Phase 3
38 Giapreza Phase 4,Phase 3
39 Angiotensinogen Phase 4,Phase 3
40 Angiotensin II Type 1 Receptor Blockers Phase 4,Phase 3
41 Sildenafil Citrate Phase 4,Phase 3,Phase 2 171599-83-0
42 Citrate Phase 4,Phase 3,Phase 2
43 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 1,Not Applicable
44 Protective Agents Phase 4,Phase 1,Not Applicable
45 Sympathomimetics Phase 4
46 Dopamine Agents Phase 4
47 Sodium Potassium Chloride Symporter Inhibitors Phase 4
48 Cardiotonic Agents Phase 4,Not Applicable
49 Autonomic Agents Phase 4,Phase 2,Not Applicable
50 Neurotransmitter Agents Phase 4,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 130)
# Name Status NCT ID Phase Drugs
1 Effects of Atorvastatin Treatment on Left Ventricular Diastolic Function in Peritoneal Dialysis Patients Unknown status NCT01503671 Phase 4 Atorvastatin
2 Novel Treatment for Diastolic Heart Failure in Women Completed NCT00206232 Phase 4 Spironolactone
3 Aldosterone Antagonism in Diastolic Heart Failure Completed NCT00108251 Phase 4 Eplerenone;Placebo
4 A Trial of Fimasartan for Early Diastolic Heart Failure Completed NCT01691118 Phase 4 Fimasartan;Antihypertensive treatment
5 Impacts of Aldosterone Blockade on Myocardial Remodeling in Hypertensive Patients With Diastolic Failing Heart Completed NCT01944384 Phase 4 aldactone
6 Efficacy and Safety of Valsartan Versus Placebo on Exercise Tolerance in Patients With Heart Failure Completed NCT00171106 Phase 4 valsartan
7 SIDAMI - Sildenafil and Diastolic Dysfunction After Acute Myocardial Infarction (AMI) Completed NCT01046838 Phase 4 Sildenafil;Placebo
8 Diuretics and Dopamine in Heart Failure With Preserved Ejection Fraction Completed NCT01901809 Phase 4 Furosemide;Dopamine
9 Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure Recruiting NCT02053246 Phase 4 Nebivolol
10 Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF Recruiting NCT02589977 Phase 4 regadenoson
11 Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction Recruiting NCT03506412 Phase 4 Entrestoâ„¢ 49Mg-51 mg tablet
12 Respiratory Muscle Function in Heart Failure Recruiting NCT03924479 Phase 4
13 Effects of Empagliflozin on Exercise Capacity and Left Ventricular Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction and Type-2 Diabetes Mellitus Recruiting NCT03753087 Phase 4 Empagliflozin
14 Reversing Endothelial and Diastolic Dysfunction and Improving Collagen Turnover in Diastolic Heart Failure Terminated NCT00293150 Phase 4 Eplerenone
15 Use of Nesiritide in the Management of Acute Diastolic Heart Failure Terminated NCT00083772 Phase 4 Nesiritide
16 Safety and Efficacy Trial to Treat Diastolic Heart Failure Using Ambrisentan Terminated NCT00840463 Phase 4 Ambrisentan
17 Evaluating the Use of Exenatide in People With Type 2 Diabetes and Diastolic Heart Failure Terminated NCT00799435 Phase 4 Exenatide
18 Estrogen Diastolic Heart Failure Terminated NCT02693002 Phase 4 Estradiol/Norethindrone acetate;Placebo
19 Denervation of the renAl sympathetIc nerveS in hearT Failure With nOrmal Lv Ejection Fraction Unknown status NCT01583881 Phase 2, Phase 3
20 A Randomized Trial of Udenafil Therapy in Patients With Heart Failure With Preserved Ejection Fraction [ULTIMATE-HFpEF] Unknown status NCT01599117 Phase 3 Placebo;Udenafil (Zydena)
21 Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study) Completed NCT00763867 Phase 3 Placebo;Sildenafil
22 Phosphodiesterase-5 (PDE5) Inhibition and Pulmonary Hypertension in Diastolic Heart Failure Completed NCT01156636 Phase 2, Phase 3 Sildenafil;Placebo
23 Evaluation of Enalapril Versus Placebo in Patients With Diastolic Heart Failure Completed NCT01411735 Phase 3 Enalapril;placebo
24 PIE II: Pharmacological Intervention in the Elderly II Completed NCT00123955 Phase 3 Spironolactone;Placebo
25 Safety and Efficacy of Bosentan in Patients With Diastolic Heart Failure and Secondary Pulmonary Hypertension Completed NCT00820352 Phase 3 bosentan;placebo
26 Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function Completed NCT00094302 Phase 3 Spironolactone;Placebo
27 Sildenafil in HFpEF (Heart Failure With Preserved Ejection Fraction) and PH Completed NCT01726049 Phase 3 Sildenafil;Placebo
28 Optimized Management of Comorbidity in Heart Failure With Preserved Ejection Fraction in the Elderly (>60 Years) Recruiting NCT02425371 Phase 3
29 Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction Active, not recruiting NCT01920711 Phase 3 LCZ696;Valsartan
30 Study of the Effect of Eplerenone on Heart Function in Women Receiving Anthracycline Chemotherapy for Breast Cancer Terminated NCT01708798 Phase 2, Phase 3 Eplerenone;Placebo
31 Study of Nesiritide in Diastolic Heart Failure. Completed NCT00309868 Phase 1, Phase 2 neseritide
32 A Study of the Effectiveness of Sitaxsentan Sodium in Patients With Diastolic Heart Failure Completed NCT00303498 Phase 2 Sitaxsentan sodium;Placebo
33 The DIAMOND Study: Distensibility Improvement And Remodeling in Diastolic Heart Failure Completed NCT00043836 Phase 2 ALT-711
34 Ranolazine in Diastolic Heart Failure Completed NCT01163734 Phase 2 Ranolazine
35 Metoprolol XR in Heart Failure With Normal Ejection Fraction Completed NCT03882710 Phase 2 Metoprolol XR
36 Perhexiline Therapy in Heart Failure With Preserved Ejection Fraction Syndrome Completed NCT00839228 Phase 2 Perhexiline;Placebo
37 Pharmacokinetics, Pharmacodynamics, and Impact of Inorganic Nitrate on Exercise in HFpEF Completed NCT02256345 Phase 2 KNO3;KCl
38 Natriuretic Peptide System as Therapy in Human Preclinical Left Ventricle Dysfunction Completed NCT00387621 Phase 1, Phase 2 Nesiritide;Placebo;Saline
39 Interleukin-1 Blockade in HF With Preserved EF Completed NCT02173548 Phase 2 Anakinra;Placebo
40 Radiofrequency-based Speckle Tracking Echocardiography to Evaluate Diastolic Function Completed NCT01182805 Phase 1, Phase 2
41 Inhaled Nitrite in Subjects With Pulmonary Hypertension Completed NCT01431313 Phase 2 Inhaled Nitrite
42 CoQ10 and D-ribose in Patients With Diastolic Heart Failure Recruiting NCT03133793 Phase 2 CoQ10;D-Ribose Oral Powder
43 Regression of Fibrosis & Reversal of Diastolic Dysfunction in HFPEF Patients Treated With Allogeneic CDCs Recruiting NCT02941705 Phase 2
44 Beginning a Randomized Evaluation of the AGE Breaker Alagebrium in Diastolic Heart Failure (BREAK-DHF-I) Terminated NCT00662116 Phase 2 alagebrium;placebo
45 A Randomized Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Effects of Alagebrium on Exercise in Subjects With Diastolic Heart Failure Terminated NCT01913301 Phase 2 Alagebrium
46 The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure Terminated NCT01887353 Phase 2 Ranolazine;Placebo
47 A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Diastolic Dysfunction Terminated NCT01172756 Phase 2 Riociguat (BAY63-2521);Riociguat (BAY63-2521);Riociguat (BAY63-2521);Placebo
48 If Channel Blockade With Ivabradine in Patients With Diastolic Heart Failure Withdrawn NCT00757055 Phase 2 Ivabradine;Placebo
49 BNP Testing in Patients With SOB on Presentation to ED Unknown status NCT00163709 Phase 1
50 Physiological Effects of Grape Seed Extract in Diastolic Heart Failure Completed NCT01185067 Phase 1 grape seed extract (MegaNatural BP, Polyphenolics, Inc.)

Search NIH Clinical Center for Diastolic Heart Failure

Cochrane evidence based reviews: heart failure, diastolic

Sources

Genetic Tests for Diastolic Heart Failure

About this section
Sources

Anatomical Context for Diastolic Heart Failure

About this section

MalaCards organs/tissues related to Diastolic Heart Failure:

42
Heart, Kidney, Testes, Brain, Endothelial, Breast, Lung
Sources

Publications for Diastolic Heart Failure

About this section

Articles related to Diastolic Heart Failure:

(show top 50) (show all 483)
# Title Authors Year
1
Adeno-associated virus 9-mediated RNA interference targeting SOCS3 alleviates diastolic heart failure in rats. ( 30763670 )
2019
2
Motivational interviewing can support physical activity in elderly patients with diastolic heart failure: results from a pilot study. ( 30963721 )
2019
3
Endomyocardial Fibrosis: A Rare Case of Diastolic Heart Failure in a European Caucasian Elderly Woman. ( 28818409 )
2018
4
Pulmonary Edema and Diastolic Heart Failure in the Perioperative Period. ( 29607222 )
2018
5
Impact of end stage renal disease on in-hospital outcomes of patients with systolic and diastolic heart failure (insights from the Nationwide Inpatient Sample 2010 to 2014). ( 29887443 )
2018
6
Deliberations on Diastolic Heart Failure. ( 28029360 )
2017
7
Age-dependent diastolic heart failure in an in vivo Drosophila model. ( 28328397 )
2017
8
Shared biomarkers between female diastolic heart failure and pre-eclampsia: a systematic review and meta-analysis. ( 28451444 )
2017
9
Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2). ( 28475816 )
2017
10
Exercise training in Diastolic Heart Failure (Ex-DHF): rationale and design of a multicentre, prospective, randomized, controlled, parallel group trial. ( 28516519 )
2017
11
Etiologies, Trends, and Predictors of 30-Day Readmissions in Patients With Diastolic Heart Failure. ( 28648393 )
2017
12
Complexity of pathomechanisms leading to diastolic heart failure in diabetes mellitus - potential field for therapeutic interventions? ( 28934928 )
2017
13
Stachydrine ameliorates pressure overload-induced diastolic heart failure by suppressing myocardial fibrosis. ( 28979698 )
2017
14
Diastolic heart failure associated with hemangiosarcoma infiltrating left ventricular walls in a dog. ( 29089652 )
2017
15
The role of Ivabradine in Diastolic Heart Failure with preserved Ejection Fraction. A Doppler-Echocardiographic study. ( 29142810 )
2017
16
Shortness of breath in clinical practice: A case for left atrial function and exercise stress testing for a comprehensive diastolic heart failure workup. ( 29354484 )
2017
17
Diastolic heart failure: diagnosis and therapy. ( 26658178 )
2016
18
Association of ACE gene D polymorphism with left ventricular hypertrophy in patients with diastolic heart failure: a case-control study. ( 26861937 )
2016
19
The Stiff Left Atrium Is to Atrial Fibrillation as the Stiff Left Ventricle Is to Diastolic Heart Failure. ( 26966289 )
2016
20
Clinical effects of combined treatment by optimal dose of furosemide and spironolactone on diastolic heart failure in elderly patients. ( 26998008 )
2016
21
Impaired Right Ventricular-Pulmonary Arterial Coupling and Effect of Sildenafil in Heart Failure With Preserved Ejection Fraction: An Ancillary Analysis From the Phosphodiesterase-5 Inhibition to Improve Clinical Status And Exercise Capacity in Diastolic Heart Failure (RELAX) Trial. ( 27072860 )
2016
22
Diastolic Heart Failure Predicted by Left Atrial Expansion Index in Patients with Severe Diastolic Dysfunction. ( 27622475 )
2016
23
Complete heart block with diastolic heart failure and pulmonary edema secondary to enlarging previously diagnosed thrombosed aneurysm of sinus of valsalva in a patient with history of autosomal dominant polycystic kidney disease. ( 25861484 )
2015
24
Constrictive pericarditis--a curable diastolic heart failure. ( 26440983 )
2015
25
Genetics of systolic and diastolic heart failure. ( 25380161 )
2015
26
Lowering body weight in obese mice with diastolic heart failure improves cardiac insulin sensitivity and function: implications for the obesity paradox. ( 25524917 )
2015
27
Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure). ( 25742762 )
2015
28
Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implications. ( 26142467 )
2015
29
Successful resection of a huge metastatic liposarcoma in the pericardium resulting in improvement of diastolic heart failure: a case report. ( 26366370 )
2015
30
Increased Prevalence of Diastolic Heart Failure in Patients with Rheumatoid Arthritis Correlates with Active Disease, but Not with Treatment Type. ( 26373561 )
2015
31
Sustained Toll-Like Receptor 9 Activation Promotes Systemic and Cardiac Inflammation, and Aggravates Diastolic Heart Failure in SERCA2a KO Mice. ( 26461521 )
2015
32
The association and interaction analysis of hypertension and diabetes mellitus on diastolic heart failure in a high-risk population. ( 26885071 )
2015
33
Constrictive pericarditis--a curable diastolic heart failure. ( 25072910 )
2014
34
Diastolic heart failure: the current understanding and approach for management with focus on intensive care unit patients. ( 22786981 )
2014
35
Digoxin and 30-day all-cause hospital admission in older patients with chronic diastolic heart failure. ( 24067296 )
2014
36
Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction - a report from the Japanese Diastolic Heart Failure Study (J-DHF). ( 24286855 )
2014
37
Connective tissue growth factor and cardiac diastolic dysfunction: human data from the Taiwan diastolic heart failure registry and molecular basis by cellular and animal models. ( 24464932 )
2014
38
Socioeconomic factors and mortality in diastolic heart failure. ( 24467732 )
2014
39
CrossTalk proposal: The late sodium current is an important player in the development of diastolic heart failure (heart failure with a preserved ejection fraction). ( 24488066 )
2014
40
CrossTalk opposing view: the late sodium current is not an important player in the development of diastolic heart failure (heart failure with a preserved ejection fraction). ( 24488067 )
2014
41
New diagnostic and therapeutic possibilities for diastolic heart failure. ( 24494212 )
2014
42
Impact of the renin-angiotensin system and inflammatory gene polymorphisms on diastolic heart failure. ( 24530241 )
2014
43
Atorvastatin ameliorates cardiac fibrosis and improves left ventricular diastolic function in hypertensive diastolic heart failure model rats. ( 24759122 )
2014
44
Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study. ( 24991733 )
2014
45
Heart failure with normal ejection fraction, heart failure with preserved ejection fraction, diastolic heart failure, or huff-puff: time for a new taxonomy for hypertensive-metabolic heart failure. ( 25151212 )
2014
46
Association and predictive value analysis for metabolic syndrome on systolic and diastolic heart failure in high-risk patients. ( 25249273 )
2014
47
Myocardial energetics and ubiquinol in diastolic heart failure. ( 25263245 )
2014
48
Utility of lower limb positive pressure test for diagnosis of diastolic heart failure: a case report. ( 25264062 )
2014
49
Increased reactive oxygen species, metabolic maladaptation, and autophagy contribute to pulmonary arterial hypertension-induced ventricular hypertrophy and diastolic heart failure. ( 25267798 )
2014
50
Optimising exercise training in prevention and treatment of diastolic heart failure (OptimEx-CLIN): rationale and design of a prospective, randomised, controlled trial. ( 25354950 )
2014
Sources

Variations for Diastolic Heart Failure

About this section
Sources

Expression for Diastolic Heart Failure

About this section
Search GEO for disease gene expression data for Diastolic Heart Failure.
Sources

Pathways for Diastolic Heart Failure

About this section

Pathways related to Diastolic Heart Failure according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Development Angiotensin activation of ERK 23
Show member pathways
 12.47 AGT AGTR1 MADD NOS3
2
Immune response IL-23 signaling pathway 23
Show member pathways
 12.14 AGTR1 MMP2 NOS3
3
AGE-RAGE signaling pathway in diabetic complications 38
11.13 AGTR1 MMP2 NOS3
4
Validated transcriptional targets of AP1 family members Fra1 and Fra2 1
10.9 MMP2 NOS3
5
A-beta Pathways: Uptake and Degradation 66
10.83 ACE MMP2
6
Plasma membrane estrogen receptor signaling 1
10.67 MMP2 NOS3
7
Renin secretion 38
10.64 ACE AGT AGTR1
8
A-beta Pathways: Plaque Formation and APP Metabolism 66
10.52 ACE MMP2
Sources

GO Terms for Diastolic Heart Failure

About this section

Cellular components related to Diastolic Heart Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sarcomere GO:0030017 8.62 MMP2 MYBPC3

Biological processes related to Diastolic Heart Failure according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 cell surface receptor signaling pathway GO:0007166 9.8 AGT MADD NPPB
2 kidney development GO:0001822 9.7 ACE AGT AGTR1
3 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.63 AGT AGTR1
4 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.63 AGT MMP2
5 sarcomere organization GO:0045214 9.62 ANKRD1 MYBPC3
6 positive regulation of protein tyrosine kinase activity GO:0061098 9.61 ACE AGT
7 positive regulation of reactive oxygen species metabolic process GO:2000379 9.61 AGT AGTR1
8 positive regulation of blood pressure GO:0045777 9.6 ACE AGT
9 cardiac muscle tissue morphogenesis GO:0055008 9.59 ANKRD1 MYBPC3
10 vasodilation GO:0042311 9.58 AGT NOS3
11 nitric oxide mediated signal transduction GO:0007263 9.58 AGT NOS3
12 positive regulation of cellular protein metabolic process GO:0032270 9.57 AGT AGTR1
13 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.56 AGT AGTR1
14 low-density lipoprotein particle remodeling GO:0034374 9.55 AGT AGTR1
15 positive regulation of renal sodium excretion GO:0035815 9.54 AGT NPPB
16 blood vessel remodeling GO:0001974 9.54 ACE AGT NOS3
17 positive regulation of cholesterol esterification GO:0010873 9.51 AGT AGTR1
18 regulation of vasoconstriction GO:0019229 9.5 ACE AGT AGTR1
19 positive regulation of NAD(P)H oxidase activity GO:0033864 9.49 AGT AGTR1
20 regulation of renal sodium excretion GO:0035813 9.48 AGT AGTR1
21 renin-angiotensin regulation of aldosterone production GO:0002018 9.46 AGT AGTR1
22 regulation of blood vessel diameter by renin-angiotensin GO:0002034 9.43 AGT AGTR1
23 regulation of blood vessel size GO:0050880 9.43 AGT NOS3 NPPB
24 regulation of renal output by angiotensin GO:0002019 9.4 ACE AGT
25 regulation of blood vessel diameter GO:0097746 9.33 ACE AGTR1 NPPB
26 regulation of blood pressure GO:0008217 9.26 ACE AGT NOS3 NPPB
27 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 8.8 ACE AGT AGTR1

Molecular functions related to Diastolic Heart Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 titin binding GO:0031432 8.96 ANKRD1 MYBPC3
2 bradykinin receptor binding GO:0031711 8.62 ACE AGTR1
Sources

Sources for Diastolic Heart Failure

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....